Manufactory Supply: Vonoprazan Fumarate (TAK-438) 99% White Powder CAS 1260141-27-2

Superiority:

English name: TAK-438 CAS number: 1260141-27-2 Molecular formula: C21H20FN3O6S Molecular weight: 461.4634032 EINECS Number: 250-635-4 Vonoprazan fumarate (TAK-438, Vonoprazanfumarate) is a new oral anti-gastric acid drug jointly launched by Takeda Pharmaceutical and Otsuka Pharmaceutical. 【Registration classification】Chemical drug category 3.1 【Indications】Used for the treatment of erosive esophagitis, gastric ulcer and duodenal ulcer. On February 28, 2014, Takeda Pharmaceutical submitted a New Drug Application (NDA) for vonoprazan (TAK-438) to the Japanese Ministry of Labor, Health and Welfare (MHLW). Takeda Pharmaceutical has conducted several Phase III clinical trials in Japan to investigate the efficacy of TAK-438 in indications for erosive esophagitis, gastric ulcer, duodenal ulcer and Helicobacter pylori eradication. In clinical trials, compared with the current proton pump inhibitors (PPIs), vonoprazan (TAK-438) has no CYP2C19 metabolism, so it has shown better efficacy in clinical trials: treatment of gastric ulcer/ten The efficacy of duodenal ulcer, reflux esophagitis, and eradication of pyloric screw is better than that of lansoprazole, and it has good tolerance and safety. On December 26, 2014, Vonoprazan fumarate (TAK-438, Vonoprazanfumarate) was approved for marketing in Japan (trade name Takecab) for the treatment of acid-related diseases. Compared with traditional irreversible proton pump inhibitors (such as omeprazole, esomeprazole, etc.), vonoprazan fumarate (Takecab) has the following advantages: (1) Rapid onset of action, and the first day of administration It will achieve the maximum acid-suppressing effect; ② Oral administration is not affected by gastric acid damage, and does not need to be in the form of enteric-coated administration; ③ It has a certain improvement on the phenomenon of acid breakthrough at night.

Treatment of duodenal ulcer, gastric ulcer and reflux esophagitis, gastric or recurrent duodenal ulcer caused by low-dose aspirin. Helicobacter pylori eradication, adjuvant treatment of the following diseases: gastric ulcer, duodenal ulcer, gastric MALT lymphoma, idiopathic thrombocytopenic purpura, early gastric cancer, Helicobacter pylori-infected gastritis.

Q1.Are you a manufacturer or a trading company
A1.Our company is a leading manufacturer specializing in trade and the development, production and marketing of pharmaceutical intermediates and apis for more than 10 years.
Q2.What about the quality of your products
A2.We value quality as life.We strictly control the quality of each process, established a perfect quality control system.
Q3.In the third quarter.What is your minimum order quantity
A3.Our minimum order quantity is 1 gram.
Q4.Fourth quarter.Can you provide free test samples
A4.Yes, we can provide 10g free samples for consumer test.
Q5.What is your delivery time
A5.Delivery takes 2-3 days, depending on the destination.
Q6.What about the mode of transportation
A6.For urgent and light orders, UPS, FedEx, DHL, EMS can be used;For heavier goods, we provide the method of air or sea transportation to consumers.
Q7.So far.How about the terms of payment
A7.We accept T/T,  Paypal, , money gram, etc.